Altamira Therapeutics Ltd. (CYTOF)

Market Cap	407.50K
Revenue (ttm)	n/a
Net Income (ttm)	-2.70M
Shares Out	3.40M
EPS (ttm)	-1.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	745,100
Open	0.138
Previous Close	0.300
Day's Range	0.101 - 0.200
52-Week Range	0.101 - 0.490
Beta	2.41
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 14, 2025

About Altamira Therapeutics

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 10
• Stock Exchange: OTCMKTS
• Ticker Symbol: CYTOF